From: A pilot study to assess the feasibility of evaluation of markers of response to chemotherapy at one day & 21 days after first cycle of chemotherapy in carcinoma of breast: a prospective non-randomized observational study
Antigen
Antibody
Manufacturer
Scoring
Ki-67
MAb
Zymed, San Francisco, CA
Nuclear staining; % positive
Bcl-2
DAKO, Carpenteria, CA
Cytoplasmic staining, % positive
Caspase-3
Mouse
Imgenex, San diego, CA
Nuclear and cytoplasm staining, % positive